Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | STAT3 | P40763 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8916560 | 0.86 | MEN1 (0.72) | MEN1KMT2AALDH1A1KDM4ETDP1 | |
| SCHEMBL8925693 | 0.85 | ALDH1A1 (0.75) | MEN1KMT2AALDH1A1KDM4ETDP1 | |
| SCHEMBL16673541 | 0.78 | FAAH (0.76) | MEN1KMT2AALDH1A1KDM4ETDP1 | |
| SCHEMBL18889391 | 0.77 | PDE3B (0.46) | MEN1KMT2AALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL12058759 | 0.76 | KMT2A (0.75) | MEN1KMT2AALDH1A1KDM4ETDP1 | |
| SCHEMBL257897 | 0.76 | MEN1 (0.64) | MEN1KMT2AL3MBTL1HTTGAA | |
| SCHEMBL8924475 | 0.74 | LMNA (0.75) | MEN1KMT2AALDH1A1KDM4ETDP1 | |
| SCHEMBL4995608 | 0.74 | MEN1 (0.56) | MEN1KMT2AALDH1A1KDM4ETDP1 | |
| SCHEMBL94838 | 0.74 | MEN1 (0.72) | MEN1KMT2AALDH1A1KDM4ETDP1 | |
| SCHEMBL903573 | 0.74 | HTT (0.65) | MEN1KMT2AKDM4ESMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129893-A1 | Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas | DUMAS JACQUES (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129893-A1 | Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas | DUMAS JACQUES (US) | 2012-05-24 | — | — | US | disclosed |
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2007-10-18 | — | — | US | disclosed |
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BRAF, RAF1, ARAF | MEN1 2248/4885KMT2A 1462/4885ALDH1A1 2759/4885 |
| US-20120129893-A1 | Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas | BRAF, RAF1, ARAF | MEN1 2248/4885KMT2A 1462/4885ALDH1A1 2759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.